

# Ming Dong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5558328/publications.pdf>

Version: 2024-02-01

6

papers

148

citations

1478505

6

h-index

1872680

6

g-index

6

all docs

6

docs citations

6

times ranked

236

citing authors

#	ARTICLE	IF	CITATIONS
1	trans-Polydatin protects the mouse heart against ischemia/reperfusion injury via inhibition of the renin-angiotensin system (RAS) and Rho kinase (ROCK) activity. Food and Function, 2017, 8, 2309-2321.	4.6	17
2	Polydatin prevents hypertrophy in phenylephrine induced neonatal mouse cardiomyocytes and pressure-overload mouse models. European Journal of Pharmacology, 2015, 746, 186-197.	3.5	22
3	Polydatin attenuates cardiac hypertrophy through modulation of cardiac Ca <sup>2+</sup> handling and calcineurin-NFAT signaling pathway. American Journal of Physiology - Heart and Circulatory Physiology, 2014, 307, H792-H802.	3.2	24
4	A combination of increased Rho kinase activity and N-terminal pro-B-type natriuretic peptide predicts worse cardiovascular outcome in patients with acute coronary syndrome. International Journal of Cardiology, 2013, 167, 2813-2819.	1.7	16
5	Increased Rho kinase activity in congestive heart failure. European Journal of Heart Failure, 2012, 14, 965-973.	7.1	40
6	Current Status of Rho-Associated Kinases (ROCKs) in Coronary Atherosclerosis and Vasospasm. Cardiovascular and Hematological Agents in Medicinal Chemistry, 2009, 7, 322-330.	1.0	29